Author:
Peterse Elisabeth F. P.,Verburg-Baltussen Elisabeth J. M.,Stewart Alexa,Liu Fei Fei,Parker Christopher,Treur Maarten,Malcolm Bill,Klijn Sven L.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference36 articles.
1. Sussman M, Crivera C, Benner J, Adair N. Applying state-of-the-art survival extrapolation techniques to the evaluation of CAR-T therapies: evidence from a systematic literature review. Adv Ther. 2021;38(8):4178–94.
2. Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011. https://www.sheffield.ac.uk/nice-dsu/tsds/flexible-methods-survival-analysis. Accessed 10 Oct 2021.
3. Kearns B, Stevens J, Ren S, Brennan A. How uncertain is the survival extrapolation? A study of the impact of different parametric survival models on extrapolated uncertainty about hazard functions, lifetime mean survival and cost effectiveness. Pharmacoeconomics. 2020;38(2):193–204.
4. Maruvka YE, Tang M, Michor F. On the validity of using increases in 5-year survival rates to measure success in the fight against cancer. PLoS ONE. 2014;9(7): e83100.
5. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000;283(22):2975–8.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献